Skip to search formSkip to main contentSkip to account menu

birinapant

Known as: Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-,(2S,2'S)- 
A synthetic small molecule that is both a peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

DipeptidesIndoles
NCIt Antineoplastic Agent Terminology

Narrower (1)

TL32711

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar)*
Despite decades of effort, pancreatic adenocarcinoma (PDAC) remains an intractable clinical challenge. An insufficient… 
2018
2018
A Nucleolar Stress–Specific p53–miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network
2018
2018
A phase 1/2 study with birinapant in combination with pembrolizumab.
TPS3131Background: Birinapant is a bivalent SMAC mimetic with activity against multiple members of the inhibitor of apoptosis… 
2017
2017
NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP
Second mitochondria-derived activator of caspases (SMAC) mimetics is a class of new anticancer agents. However, most cancers… 
2017
2017
Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to… 
2016
2016
Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer currently lacking targeted therapies. Our… 
2015
2015
A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian…
5571 Background: Treating patients (pts) with relapsed ovarian cancer remains challenging. Birinapant is a bivalent SMAC mimetic… 
2013
2013
A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
2504 Background: Birinapant (B) is a SMAC-mimetic that inhibits IAPs with excellent tolerability, drug exposure, target… 
2012
2012
On the prevalence and causes of oncologist burnout.
2012
2012
Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens.
3029 Background: Birinapant is a novel small molecule Smac-mimetic that targets members of the inhibitor of apoptosis proteins… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)